KM Research Hub
← 返回论文库
部分完成 入排:符合 图源:可得 入排置信度 0.98

Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE.

Jennifer R Brown, Barbara Eichhorst, Nicole Lamanna, Susan M O'Brien, Constantine S Tam, Lugui Qiu, Wojciech Jurczak, Keshu Zhou, Martin Šimkovič, Jiří Mayer, Amanda Gillespie-Twardy, Alessandra Ferrajoli, Peter S Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Osterborg, Habte A Yimer, Megan Wang, Tommi Salmi, Liping Wang, Jessica Li, Kenneth Wu, Aileen Cohen, Mazyar Shadman

Blood 144(26) 2706-2717

PMID39316666
PMCIDPMC11738031
DOI10.1182/blood.2024024667
发表日期2024-09-24
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

The ALPINE trial established the superiority of zanubrutinib over ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma; here, we present data from the final comparative analysis with extended follow-up. Overall, 652 patients received zanubrutinib (n = 327) or ibrutinib (n = 325). At an overall median follow-up of 42.5 months, progression-free survival benefit with zanubrutinib vs ibrutinib was sustained (hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.54-0.84), including in patients with del(17p)/TP53 mutation (HR, 0.51; 95% CI, 0.33-0.78) and across multiple sensitivity analyses. Overall response rate remained higher with zanubrutinib compared with ibrutinib (85.6% vs 75.4%); responses deepened over time with complete response/complete response with incomplete bone marrow recovery rates of 11.6% (zanubrutinib) and 7.7% (ibrutinib). Although median overall survival has not been reached in either treatment group, fewer zanubrutinib patients have died than ibrutinib patients (HR, 0.77 [95% CI, 0.55-1.06]). With median exposure time of 41.2 and 37.8 months in zanubrutinib and ibrutinib arms, respectively, the most common nonhematologic adverse events included COVID-19-related infection (46.0% vs 33.3%), diarrhea (18.8% vs 25.6%), upper respiratory tract infection (29.3% vs 19.8%), and hypertension (27.2% vs 25.3%). Cardiac events were lower with zanubrutinib (25.9% vs 35.5%) despite similar rates of hypertension. Incidence of atrial fibrillation/flutter was lower with zanubrutinib vs ibrutinib (7.1% vs 17.0%); no cardiac deaths were reported with zanubrutinib vs 6 cardiac deaths with ibrutinib. This analysis, at 42.5 months median follow-up, demonstrates that zanubrutinib remains more efficacious than ibrutinib with an improved overall safety/tolerability profile. This trial was registered at www.ClinicalTrials.gov as #NCT03734016.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

Figure 6.

Time to cardiac disorders and cardiovascular AEs of interest. (A) Time to occurrence of cardiac disorders; based on MedDRA version 26.0 cardiac disorder system organ class. (B) Time to occurrence of atrial fibrillation or flutter. (C) Time to occurrence of hypertension.

A

Time to occurrence of cardiac disorders

Figure 6. · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Figure 6. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:off origin start曲线 2:off origin start曲线 2:extreme upward reversal
查看结果
B

Time to occurrence of atrial fibrillation or flutter

Figure 6. · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Figure 6. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
C

Time to occurrence of hypertension

Figure 6. · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 Figure 6. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 1:off origin start
查看结果
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1无图注
非 KM Figure
Figure 1.Study flow.
非 KM Figure
Figure 2.Investigator-assessed PFS and OS. (A) PFS in the overall population. (B) PFS in patients with del(17p)/ TP53 mut . (C) PFS when assessing only for progression or death events occurring on active treatment. (D) PFS when adjusted for COVID-19 deaths. (E) OS.
非 KM Figure
Figure 3.Yearly prevalence of clinically relevant AEs from 0 to 48 months. Pooled MedDRA preferred terms for all reported AEs.
非 KM Figure
Figure 4.Most common treatment-emergent AEs. (A) All-grade treatment-emergent AEs occurring in ≥15% of patients. (B) Most common grade ≥3 treatment-emergent AEs. Value reported in cumulative prevalence rate at 42.5-month follow-up. Dark fill indicates percent of patients with an AE at 29.6-month median follow-up; lighter fill indicates change in percent of patients with AE from 29.6 months to 42.5-month median follow-up. URTI, upper respiratory tract infection.
非 KM Figure
Figure 5.Mean change from baseline in systolic and diastolic blood pressure. (A) Mean change from baseline in systolic blood pressure. (B) Mean change from baseline in diastolic blood pressure. SEM, standard error of the mean.
非 KM Figure